Arovella Therapeutics Ltd
ASX:ALA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Arovella Therapeutics Ltd
ASX:ALA
|
AU |
|
Chemours Co
NYSE:CC
|
US |
|
Sharda Cropchem Ltd
NSE:SHARDACROP
|
IN |
|
F
|
Fastenal Co
F:FAS
|
US |
|
Lammhults Design Group AB
STO:LAMM B
|
SE |
|
Baazeem Trading Company CJSC
SAU:4051
|
SA |
|
Enervit SpA
MIL:ENV
|
IT |
|
New Talisman Gold Mines Ltd
NZX:NTL
|
NZ |
|
STO Express Co Ltd
SZSE:002468
|
CN |
|
Supreme Engineering Ltd
NSE:SUPREMEENG
|
IN |
|
D
|
Dadelo SA
WSE:DAD
|
PL |
|
S
|
South Malaysia Industries Bhd
KLSE:SMI
|
MY |
|
Z
|
Zhejiang Sunrise Garment Group Co Ltd
SSE:605138
|
CN |
|
Ferrovial SE
AEX:FER
|
NL |
|
Magnet Forensics Inc
TSX:MAGT
|
CA |
|
Kasen International Holdings Ltd
HKEX:496
|
CN |
|
Centrotherm International AG
F:CTNK
|
DE |
|
E
|
Endurance Technologies Ltd (CN)
NSE:ENDURANCE
|
IN |
|
Austin Engineering Ltd
ASX:ANG
|
AU |
|
J
|
JCK Hospitality PCL
SET:JCKH
|
TH |
|
Huaneng Power International Inc
SSE:600011
|
CN |
|
SL Green Realty Corp
NYSE:SLG
|
US |
Arovella Therapeutics Ltd
Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.
Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.
